Neuronetics Future Growth

Future criteria checks 1/6

Neuronetics is forecast to grow earnings and revenue by 30.9% and 13.7% per annum respectively while EPS is expected to grow by 34.9% per annum.

Key information

30.9%

Earnings growth rate

34.9%

EPS growth rate

Medical Equipment earnings growth16.8%
Revenue growth rate13.7%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Jun 2024

Recent future growth updates

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet

May 24
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Neuronetics: Reality Set In

May 09

Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower

May 08
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower

Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

May 01
Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Mar 17
Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Neuronetics: Modest Improvements Are Not Enough

Jan 30

Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Dec 19
Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Jun 21
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

May 10
Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

Neuronetics: Growth To Capture, But Fairly Priced

Sep 06

Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Sep 06
Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Aug 29

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Aug 02

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

Jul 19

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Jun 08
Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Jan 19
Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Earnings and Revenue Growth Forecasts

NasdaqGM:STIM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026104-14N/AN/A2
12/31/202590-20N/AN/A4
12/31/202479-28N/AN/A4
3/31/202473-28-31-29N/A
12/31/202371-30-34-32N/A
9/30/202369-33-39-37N/A
6/30/202368-31-36-34N/A
3/31/202367-37-36-34N/A
12/31/202265-37-34-31N/A
9/30/202262-37-36-32N/A
6/30/202259-37-37-34N/A
3/31/202257-34-34-31N/A
12/31/202155-31-30-28N/A
9/30/202156-27-27-25N/A
6/30/202155-22-22-20N/A
3/31/202150-23-25-24N/A
12/31/202049-27-29-28N/A
9/30/202051-31-34-33N/A
6/30/202055-35-38-37N/A
3/31/202061-34-35-35N/A
12/31/201963-29-31-30N/A
9/30/201961-28-27-26N/A
6/30/201959-26-25-24N/A
3/31/201955-26-23-22N/A
12/31/201853-24-22-21N/A
9/30/201849-23-19-18N/A
6/30/201846-22-16-15N/A
3/31/201843-17-14-13N/A
12/31/201740-16N/A-11N/A
12/31/201634-11N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: STIM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STIM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STIM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STIM's revenue (13.7% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: STIM's revenue (13.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if STIM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.